Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$73.65 ▲ +0.36
(+0.49%)
MKT CAP: $1.08B • VOL: 358.8K
52W L $57 52W H $155
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$62
MEDIAN
$82
MEAN
$84
HIGH
$100
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INBX TAPE
INBX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $89.12 | $84.70 | 2025-02-14 | $67.02 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $92.80 | $86.91 | 2025-02-06 | $69.23 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $83.96 | $81.02 | 2025-01-29 | $70.70 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $75.12 | — | 2025-01-17 | $72.18 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $64.81 | $69.97 | 2025-01-09 | $65.55 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $87.64 | $76.60 | 2024-12-18 | $64.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $71.44 | $74.39 | 2024-12-04 | $68.49 | -4.3% | 48% | C |